416 related articles for article (PubMed ID: 33936117)
1. Analysis of Tumor Microenvironment Characteristics in Bladder Cancer: Implications for Immune Checkpoint Inhibitor Therapy.
Chen X; Chen H; He D; Cheng Y; Zhu Y; Xiao M; Lan H; Wang Z; Cao K
Front Immunol; 2021; 12():672158. PubMed ID: 33936117
[TBL] [Abstract][Full Text] [Related]
2. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC).
Cao R; Yuan L; Ma B; Wang G; Tian Y
Cancer Immunol Immunother; 2021 Jan; 70(1):1-18. PubMed ID: 32617668
[TBL] [Abstract][Full Text] [Related]
3. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.
Yan Y; Huang Z; Cai J; Tang P; Zhang F; Tan M; Shen B
Aging (Albany NY); 2020 Dec; 13(2):2780-2802. PubMed ID: 33408272
[TBL] [Abstract][Full Text] [Related]
5. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
Front Immunol; 2021; 12():791924. PubMed ID: 34975891
[TBL] [Abstract][Full Text] [Related]
6. Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model.
Zheng K; Hai Y; Chen H; Zhang Y; Hu X; Ni K
J Transl Med; 2024 Apr; 22(1):365. PubMed ID: 38632658
[TBL] [Abstract][Full Text] [Related]
7. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.
Deng B; Park JH; Ren L; Yew PY; Kiyotani K; Antic T; O'Connor K; O'Donnell PH; Nakamura Y
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1002. PubMed ID: 32729250
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analyses of a tumor-infiltrating lymphocytes-related gene signature regarding the prognosis and immunologic features for immunotherapy in bladder cancer on the basis of WGCNA.
He Z; Gu J; Luan T; Li H; Li C; Chen Z; Luo E; Wang J; Huang Y; Ding M
Front Immunol; 2022; 13():973974. PubMed ID: 36211333
[TBL] [Abstract][Full Text] [Related]
9. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
Jiang W; Zhu D; Wang C; Zhu Y
Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
[TBL] [Abstract][Full Text] [Related]
10. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment.
Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z
Front Immunol; 2021; 12():691811. PubMed ID: 34489938
[TBL] [Abstract][Full Text] [Related]
11. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
12. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
13. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
14. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
[TBL] [Abstract][Full Text] [Related]
15. m
Zhang B; Wu Q; Li B; Wang D; Wang L; Zhou YL
Mol Cancer; 2020 Mar; 19(1):53. PubMed ID: 32164750
[TBL] [Abstract][Full Text] [Related]
16. CD8
Chen X; Xu R; He D; Zhang Y; Chen H; Zhu Y; Cheng Y; Liu R; Zhu R; Gong L; Xiao M; Wang Z; Deng L; Cao K
Oncogene; 2021 Oct; 40(43):6223-6234. PubMed ID: 34552192
[TBL] [Abstract][Full Text] [Related]
17. The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
Komura K; Hirosuna K; Tokushige S; Tsujino T; Nishimura K; Ishida M; Hayashi T; Ura A; Ohno T; Yamazaki S; Nakamori K; Kinoshita S; Maenosono R; Ajiro M; Yoshikawa Y; Takai T; Tsutsumi T; Taniguchi K; Tanaka T; Takahara K; Konuma T; Inamoto T; Hirose Y; Ono F; Shiraishi Y; Yoshimi A; Azuma H
Mol Cancer; 2023 Nov; 22(1):185. PubMed ID: 37980528
[TBL] [Abstract][Full Text] [Related]
18. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
[TBL] [Abstract][Full Text] [Related]
19. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
20. Identification of Immune-Related Subtypes and Characterization of Tumor Microenvironment Infiltration in Bladder Cancer.
Huang M; Liu L; Zhu J; Jin T; Chen Y; Xu L; Cheng W; Ruan X; Su L; Meng J; Lu X; Yan F
Front Cell Dev Biol; 2021; 9():723817. PubMed ID: 34532318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]